First in-human milestone reached for MicroBlate™ Flex as part of Lung Tissue ablation clinical study

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that, further to the update of 31 March 2023, the first in-human use of the Company’s MicroBlate Flex device for the microwave (MW) ablation of soft tissue lung lesions was successfully completed at Royal Brompton Hospital, part of Guy’s and St Thomas’ NHS Foundation Trust, by Professor Pallav L Shah.

Creo’s MicroBlate Flex device is a new soft tissue ablation device which is designed with the aim of being able to ablate nodules and tumors in several tissue types using the highest frequency MW energy for tumour ablation.

The aforementioned procedure forms part of a multi-site clinical trial, with all patients having regular follow-up assessments post-procedure to monitor their progress. The Study is the first of a number of planned studies regarding the Company’s suite of ablation devices during 2023 and beyond.

Craig Gulliford, Chief Executive Officer of Creo, commented:

This is another landmark moment for Creo Medical. Lung cancer has the second highest incidence of the top 5 cancers and one of the lowest 5-year survival rates. Unlike most other cancers; there are no significant, accurate screening programmes in place for lung cancer but with screening, diagnosis and navigation technology advancing dramatically over recent years, we are set to see that change.

The goal of screening is to find the disease early when the tumours are small. However, currently the treatment options for these early-stage lesions are inappropriately invasive, typically involving chemotherapy, radiation therapy, surgery or a combination thereof.

MicroBlate Flex has been designed for a range of different applications, including the capability of operating with these new lung cancer diagnosis and navigation technologies, and is ideal for the targeted ablation of pre-cancerous and potentially cancerous lesions in the lung and in other soft tissue. Like with all our products now in clinical practice in the gastroenterology market, we hope that our technology will enable clinicians to significantly impact on the improvement of Cancer outcomes.

The whole team at Creo are delighted that this clinical program has now started. The first enrolment and MicroBlate Flex’s first procedure safely completed is an important milestone in our goal to use advanced energy to transform lives

Professor Shah added:

The ablate device is another tool in our armoury for treating early lung cancers or metastatic tumours in the lung. It provides an alternative approach when surgery is not possible and may have the potential to create a very controlled ablation minimising any additional lung damage. The current trial should help evaluate its safety and role in thoracic cancers.

Posted 05/23/23

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi

Read

31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific

Read

10 January 2024

First Use of Speedboat® UltraSlim in Latin America

Read

13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch

Read

01 November 2023

Speedboat® UltraSlim: US FDA Clearance

Read

25 October 2023

Speedboat UltraSlim: EU launch accelerated by 18 months

Read

12 September 2023

Half Year Report: H1-2023

Read

19 June 2023

Speedboat Inject cleared for upper GI use in Europe

Read

01 June 2023

Speedboat™ Inject selected by NICE for assessment

Read

17 May 2023

Royal Oldham becomes first NHS hospital to immediately implement CROMA and Speedboat™ Inject across multiple endoscopy rooms

Read